← brief for 2026-09-27 · Slowing decline
Semaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementation
Key takeaways
Who did this work
Fayez Salahedin Alkhateeb (University of Jordan)
Source
Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-26
https://doi.org/10.1007/s42399-026-02716-x